Sign inJoin
Company / Finance

Bristol Myers Squibb Company

BMY · NYSE

Bristol Myers Squibb reported Q1 2026 revenue of $11.49 billion, net income of $2.68 billion and cash of $9.57 billion. The thesis depends on new product growth, loss-of-exclusivity management, pipeline execution and debt/cash discipline.

FollowAdd to WatchlistAsk Question
NYSEBMYCoverage BootstrapBristol Myers Squibb Company
Latest ReportMay 20, 2026Bristol Myers: the patent cliff has to meet a real pipeline bridgeView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
BMYNYSE
Clear tags
MatchAny tagAll tags
Latest Thesis

Bristol Myers: the patent cliff has to meet a real pipeline bridge

Bristol Myers Squibb reported Q1 2026 revenue of $11.49 billion, net income of $2.68 billion and cash of $9.57 billion. The thesis depends on new product growth, loss-of-exclusivity management, pipeline execution and debt/cash discipline.

May 20, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Bristol Myers Squibb CompanyMyers: the patent cliff has to meet a real pipeline bridgeMay 20, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Bristol Myers: the patent cliff has to meet a real pipeline bridgeBristol Myers Squibb reported Q1 2026 revenue of $11.49 billion, net income of $2.68 billion and cash of $9.57 billion. The thesis depends on new product growth, loss-of-exclusivity management, pipeline execution and debt/cash discipline.NYSEMay 20, 2026Research reportReadSlides